Equities analysts predict that Kamada Ltd. (NASDAQ:KMDA) will report earnings per share of $0.02 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada’s earnings, with the highest EPS estimate coming in at $0.06 and the lowest estimate coming in at ($0.02). The business is expected to report its next quarterly earnings report on Monday, November 12th.
On average, analysts expect that Kamada will report full-year earnings of $0.21 per share for the current fiscal year, with EPS estimates ranging from $0.00 to $0.35. For the next fiscal year, analysts anticipate that the business will post earnings of $0.40 per share, with EPS estimates ranging from $0.27 to $0.52. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Kamada.
Kamada (NASDAQ:KMDA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.05. Kamada had a net margin of 11.79% and a return on equity of 14.43%. The business had revenue of $33.84 million during the quarter, compared to analysts’ expectations of $29.64 million.
Several research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a report on Friday, August 10th. BidaskClub upgraded shares of Kamada from a “hold” rating to a “buy” rating in a research note on Thursday, September 27th. ValuEngine upgraded shares of Kamada from a “sell” rating to a “hold” rating in a research note on Monday, July 30th. Finally, HC Wainwright set a $11.00 price target on shares of Kamada and gave the company a “buy” rating in a research note on Wednesday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Kamada has an average rating of “Buy” and an average target price of $8.08.
KMDA traded down $0.16 during trading hours on Thursday, hitting $5.81. 100 shares of the company’s stock were exchanged, compared to its average volume of 20,107. Kamada has a 1-year low of $4.26 and a 1-year high of $6.45. The stock has a market capitalization of $249.63 million, a price-to-earnings ratio of 32.28 and a beta of 1.20. The company has a current ratio of 3.95, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01.
A number of hedge funds have recently made changes to their positions in KMDA. Acadian Asset Management LLC lifted its stake in Kamada by 157.8% in the second quarter. Acadian Asset Management LLC now owns 292,795 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 179,237 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Kamada by 8.1% in the second quarter. Renaissance Technologies LLC now owns 464,900 shares of the biotechnology company’s stock valued at $2,417,000 after acquiring an additional 34,800 shares during the last quarter. Jane Street Group LLC acquired a new stake in Kamada in the second quarter valued at $146,000. Macquarie Group Ltd. lifted its stake in Kamada by 71.7% in the second quarter. Macquarie Group Ltd. now owns 47,547 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 19,851 shares during the last quarter. Finally, ARK Investment Management LLC lifted its stake in Kamada by 14.8% in the second quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock valued at $616,000 after acquiring an additional 15,440 shares during the last quarter. Hedge funds and other institutional investors own 11.24% of the company’s stock.
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).
See Also: Find a Trading Strategy That Works
Get a free copy of the Zacks research report on Kamada (KMDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.